People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Other, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neutron Holdings, Inc. | — | Other | Series D+ | $849.7M | $2.1B | 2019 |
| NewLimit, Inc. | — | Biotechnology | Series D+ | $202.0M | $1.1B | 2023 |
| Magenta Therapeutics, Inc. | — | Biotechnology | Series C | $116.0M | $2.1B | 2017 |
| Spotlight Therapeutics, Inc. | — | Biotechnology | Series B | $61.6M | $687.7M | 2017 |
| ionQ, Inc. | — | Other Technology | Series A | $14.0M | $332.9M | 2016 |
Blake Byers at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Blake Byers on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeff Jordan | 1 | 12 |
| Bruce Booth | 1 | 12 |
| Ron Bernal | 1 | 10 |
| Brian Armstrong | 1 | 8 |
| John Davis | 1 | 7 |
| Alexis Borisy | 1 | 6 |
| Michael Polansky | 1 | 6 |
| JASON GARDNER | 1 | 5 |
| Joe Kraus | 1 | 5 |
| Thomas Laffont | 1 | 5 |
| Thomas Daniel | 1 | 4 |
| Zhoujia Bao | 1 | 4 |
| Jeffrey Albers | 1 | 3 |
| Zavain Dar | 1 | 3 |
| Weiyao Sun | 1 | 3 |
| Andrew Schoen | 1 | 3 |
| Alexander Marson | 1 | 2 |
| Mary Haak-Frendscho | 1 | 2 |
| Li Fan | 1 | 2 |
| Michael Bonney | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.